Gene Biotherapeutics Inc
OTC:CRXM

Watchlist Manager
Gene Biotherapeutics Inc Logo
Gene Biotherapeutics Inc
OTC:CRXM
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 64.9 USD

Net Margin
Gene Biotherapeutics Inc

0%
Current
0%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-517.9k
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Gene Biotherapeutics Inc
Glance View

Market Cap
64.9 USD
Industry
Biotechnology

Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company is headquartered in San Diego, California. The company went IPO on 2001-07-12. The firm is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for primarily for the treatment of cardiovascular disease. The Company’s technology platform is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Generx has been cleared Phase III clinical study, the AFFIRM study.

CRXM Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-517.9k
/
Revenue
0
What is the Net Margin of Gene Biotherapeutics Inc?

Based on Gene Biotherapeutics Inc's most recent financial statements, the company has Net Margin of 0%.

Back to Top